Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems

Detalhes bibliográficos
Autor(a) principal: Patriota, Yuri B. G.
Data de Publicação: 2021
Outros Autores: Chaves, Luíse L., Gocke, Evren H., Severino, Patricia, Soares, Mônica F. R., Soares-Sobrinho, José L., Souto, Eliana B.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/1822/72485
Resumo: Heparin-based delivery systems have been explored to improve their therapeutic efficacy and to reduce toxicity for different administration routes. Regardless of the applied drug delivery system (DDS), the evaluation of anticoagulant performance is instrumental for the development of a suitable DDS. The understanding of the range of anticoagulant assays, together with their key applications and limitations, is essential both within the context of scientific research and for clinical usage. This review provides an overview of the current anticoagulant therapy and discusses the advantages and limitations of currently available anticoagulant assays. We also discuss studies involving low-molecular-weight heparin (LMWH)-based nanocarriers with emphasis on their anticoagulation performance. Conventional anticoagulants have been used for decades for the treatment of many diseases. Direct oral anticoagulants have overcome some limitations of heparins and vitamin K antagonists. However, the lack of an accurate laboratory assessment, as well as the lack of a factor xaban (Xa) inhibitor reversal agent, remains a major problem associated with these anticoagulants. LMWHs represent anticoagulant agents with noteworthy efficacy and safety, and they have been explored to improve their outcomes with various nanocarriers through several administration routes. The main problems related to LMWHs have been surmounted, and improved efficiency may be achieved through the use of DDSs.
id RCAP_f53088df8a424f3c24cecbe269c9afdb
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/72485
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systemsHeparinAnticoagulant drugsDrug delivery systemsAnticoagulant assaysHeparin-based delivery systems have been explored to improve their therapeutic efficacy and to reduce toxicity for different administration routes. Regardless of the applied drug delivery system (DDS), the evaluation of anticoagulant performance is instrumental for the development of a suitable DDS. The understanding of the range of anticoagulant assays, together with their key applications and limitations, is essential both within the context of scientific research and for clinical usage. This review provides an overview of the current anticoagulant therapy and discusses the advantages and limitations of currently available anticoagulant assays. We also discuss studies involving low-molecular-weight heparin (LMWH)-based nanocarriers with emphasis on their anticoagulation performance. Conventional anticoagulants have been used for decades for the treatment of many diseases. Direct oral anticoagulants have overcome some limitations of heparins and vitamin K antagonists. However, the lack of an accurate laboratory assessment, as well as the lack of a factor xaban (Xa) inhibitor reversal agent, remains a major problem associated with these anticoagulants. LMWHs represent anticoagulant agents with noteworthy efficacy and safety, and they have been explored to improve their outcomes with various nanocarriers through several administration routes. The main problems related to LMWHs have been surmounted, and improved efficiency may be achieved through the use of DDSs.This work was supported by the Banco do Nordeste (grant FUNDECI/2016.0015), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Apoio à Pesquisa e à Inovação Tecnológica do Estado de Sergipe (Fapitec), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). Eliana B. Souto would like to acknowledge the Portuguese Science and Technology Foundation (FCT/MCT) and the European Funds (PRODER/COMPETE) for the project UIDB/04469/2020 (strategic fund), co-financed by FEDER, under the Partnership Agreement PT2020.info:eu-repo/semantics/publishedVersionMDPIUniversidade do MinhoPatriota, Yuri B. G.Chaves, Luíse L.Gocke, Evren H.Severino, PatriciaSoares, Mônica F. R.Soares-Sobrinho, José L.Souto, Eliana B.2021-052021-05-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/72485engPatriota, Yuri B. G.; Chaves, Luíse L.; Gocke, Evren H.; Severino, Patricia; Soares, Mônica F. R.; Soares-Sobrinho, José L.; Souto, Eliana, Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems. Applied Nano, 2(2), 98-117, 20212673-350110.3390/applnano2020009https://www.mdpi.com/2673-3501/2/2/9info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:13:13Zoai:repositorium.sdum.uminho.pt:1822/72485Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:05:16.287487Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems
title Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems
spellingShingle Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems
Patriota, Yuri B. G.
Heparin
Anticoagulant drugs
Drug delivery systems
Anticoagulant assays
title_short Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems
title_full Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems
title_fullStr Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems
title_full_unstemmed Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems
title_sort Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems
author Patriota, Yuri B. G.
author_facet Patriota, Yuri B. G.
Chaves, Luíse L.
Gocke, Evren H.
Severino, Patricia
Soares, Mônica F. R.
Soares-Sobrinho, José L.
Souto, Eliana B.
author_role author
author2 Chaves, Luíse L.
Gocke, Evren H.
Severino, Patricia
Soares, Mônica F. R.
Soares-Sobrinho, José L.
Souto, Eliana B.
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Patriota, Yuri B. G.
Chaves, Luíse L.
Gocke, Evren H.
Severino, Patricia
Soares, Mônica F. R.
Soares-Sobrinho, José L.
Souto, Eliana B.
dc.subject.por.fl_str_mv Heparin
Anticoagulant drugs
Drug delivery systems
Anticoagulant assays
topic Heparin
Anticoagulant drugs
Drug delivery systems
Anticoagulant assays
description Heparin-based delivery systems have been explored to improve their therapeutic efficacy and to reduce toxicity for different administration routes. Regardless of the applied drug delivery system (DDS), the evaluation of anticoagulant performance is instrumental for the development of a suitable DDS. The understanding of the range of anticoagulant assays, together with their key applications and limitations, is essential both within the context of scientific research and for clinical usage. This review provides an overview of the current anticoagulant therapy and discusses the advantages and limitations of currently available anticoagulant assays. We also discuss studies involving low-molecular-weight heparin (LMWH)-based nanocarriers with emphasis on their anticoagulation performance. Conventional anticoagulants have been used for decades for the treatment of many diseases. Direct oral anticoagulants have overcome some limitations of heparins and vitamin K antagonists. However, the lack of an accurate laboratory assessment, as well as the lack of a factor xaban (Xa) inhibitor reversal agent, remains a major problem associated with these anticoagulants. LMWHs represent anticoagulant agents with noteworthy efficacy and safety, and they have been explored to improve their outcomes with various nanocarriers through several administration routes. The main problems related to LMWHs have been surmounted, and improved efficiency may be achieved through the use of DDSs.
publishDate 2021
dc.date.none.fl_str_mv 2021-05
2021-05-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1822/72485
url http://hdl.handle.net/1822/72485
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Patriota, Yuri B. G.; Chaves, Luíse L.; Gocke, Evren H.; Severino, Patricia; Soares, Mônica F. R.; Soares-Sobrinho, José L.; Souto, Eliana, Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems. Applied Nano, 2(2), 98-117, 2021
2673-3501
10.3390/applnano2020009
https://www.mdpi.com/2673-3501/2/2/9
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799132464266870784